WebPrelude Therapeutics reported an EPS of -$0.63 in its last earnings report, beating expectations of -$0.636. Following the earnings report the stock price went down -8.824%. Which hedge fund is a major shareholder of Prelude Therapeutics? WebApr 11, 2024 · Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s diverse pipeline is comprised of highly differentiated, potentially best-in-class or first-in-class proprietary small molecule compounds aimed at addressing clinically …
Prelude Therapeutics Incorporated Common Stock (PRLD)
WebFeb 22, 2024 · 6 Prelude Therapeutics reviews. A free inside look at company reviews and salaries posted anonymously by employees. WebAug 25, 2024 · Prelude Services has an overall rating of 3.7 out of 5, based on over 22 reviews left anonymously by employees. 73% of employees would recommend working at … ld robinson pavilion katy
Prelude Therapeutics Announces Third Quarter 2024 Financial …
WebDec 16, 2024 · Latest Prelude Therapeutics Inc Stock News. As of December 15, 2024, Prelude Therapeutics Inc had a $248.9 million market capitalization, putting it in the 44th percentile of companies in the Biotechnology & Medical Research industry. Prelude Therapeutics Inc does not have a meaningful P/E due to negative earnings over the last … WebSan Francisco Bay Area (Hybrid) Associate Director, R&D Informatics. Science, Information Technology. Wilmington, Delaware, United States (Hybrid) Clinical Trial Manager. Research, Science. United ... WebMar 15, 2024 · WILMINGTON, Del., March 15, 2024 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced a clinical trial collaboration with BeiGene, for future evaluation of its investigational CDK9 inhibitor, PRT2527, in combination with BeiGene’s BTK inhibitor, … ld piston\\u0027s